JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Effectiveness and Safety of CNTO6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: CNTO 6785
Drug: Placebo

First Posted Date: 2013-10-21

Last Posted Date: 2016-06-08

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 187

Registration Number: NCT01966549

A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum

Phase 2

Completed

Conditions: Pyoderma Gangrenosum

Interventions: Biological: Xilonix

First Posted Date: 2013-10-18

Last Posted Date: 2025-03-30

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 10

Registration Number: NCT01965613

Locations: 🇺🇸
XBiotech Investigative Site, Tallahassee, Florida, United States

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42165279 in Healthy Young and Elderly Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-42165279 100 mg
Drug: JNJ-42165279 50 mg
Drug: JNJ-42165279 30 mg
Drug: Placebo

First Posted Date: 2013-10-17

Last Posted Date: 2014-12-03

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 40

Registration Number: NCT01964651

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma

Phase 1

Completed

Conditions: Lymphoma
Neoplasms
Adenocarcinoma
Esophagogastric Junction

First Posted Date: 2013-10-14

Last Posted Date: 2019-05-15

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 19

Registration Number: NCT01962532

A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis

Phase 2

Completed

Conditions: Colitis, Ulcerative

Interventions: Drug: Placebo
Drug: JNJ-54781532 25 mg once daily
Drug: JNJ-54781532 75 mg twice daily
Drug: JNJ-54781532 75 mg once daily
Drug: JNJ-54781532 150 mg once daily

First Posted Date: 2013-10-10

Last Posted Date: 2019-01-04

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 219

Registration Number: NCT01959282

A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder

Phase 2

Terminated

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo
Drug: Ketamine

First Posted Date: 2013-10-08

Last Posted Date: 2017-01-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 13

Registration Number: NCT01957410

A Non-drug Study Profiling Cutaneous Lupus

Completed

Conditions: Lupus Erythematosus, Discoid
Lupus Erythematosus, Cutaneous
Lupus Erythematosus, Systemic

Interventions: Procedure: No intervention, skin biopsy
Procedure: No intervention, blood collection
Procedure: No intervention, urine collection

First Posted Date: 2013-08-15

Last Posted Date: 2014-09-12

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 29

Registration Number: NCT01923415

An Efficacy And Safety Study of CNTO 6785 In Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: CNTO 6785 100 mg
Drug: CNTO 6785 50 mg
Drug: CNTO 6785 15 mg
Drug: CNTO 6785 200 mg
Drug: Methotrexate (MTX)

First Posted Date: 2013-07-26

Last Posted Date: 2016-03-02

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 257

Registration Number: NCT01909427

An Observational Study to Assess the Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Users of Proton Pump Inhibitors, and Users of Metoclopramide

Completed

Conditions: Death, Sudden, Cardiac

Interventions: Drug: No intervention

First Posted Date: 2013-07-25

Last Posted Date: 2015-05-19

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 15000

Registration Number: NCT01907633

A Crossover Study to Evaluate the Effect of JNJ-54452840 on Pharmacodynamics of Metoprolol Tartrate Immediate-Release in Healthy Participants

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: Metoprolol tartrate immediate-release (metoprolol IR)
Drug: JNJ-54452840
Drug: Placebo

First Posted Date: 2013-07-18

Last Posted Date: 2016-11-01

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT01902550

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy